Celsee continues to expand its intellectual property in single-cell analysis Celsee Diagnostics, an innovator in microfluidic rare-cell isolation, characterization and retrieval platforms announced today the receipt of three additional US patents for their single cell capture and analysis technologies, adding to the company’s expanding IP library. U.S. Patent No. 9610581 B2, “System and Method for […]

Read more

Innovative platform streamlines rare single-cell enrichment, characterization and retrieval Celsee Diagnostics, an innovator of cutting-edge microfluidic products for rare cell capture, characterization and retrieval, announced today that they are demonstrating their latest innovation, Celsee PREP SingleCell at the AACR Annual Meeting 2017. Single-cell analysis is used in a vast array of life science disciplines and […]

Read more

Celsee Diagnostics, an innovator of cutting-edge rare and single cell detection products, announced the appointment of John L. “Kip” Miller to its Board of Directors. Mr. Miller is an accomplished executive and entrepreneur with a proven track record of developing and growing global life science businesses, most notably at Life Technologies (now ThermoFisher Scientific) and […]

Read more

Collaborative studies will focus on the use of circulating tumor cells (CTCs) as a biospecimen for PD-L1 quantification and as a tool for tailoring therapy in metastatic lung cancer. Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy and rare-cell detection products, and IncellDx, a single-cell diagnostic company offering transformative diagnostic and prognostic clinical patient information based […]

Read more

International standard registration will facilitate access to new markets Celsee Diagnostics, an innovator of cutting-edge rare cell isolation and characterization products for both clinical and research applications announced today its successful ISO13485:2003 registration ISO 13485, Medical devices – Quality management systems – Requirements for regulatory purposes, is an internationally agreed standard that sets out the requirements […]

Read more

Zomedica Pharmaceuticals Corp, (TSX-V:ZOM), a veterinary pharmaceutical and health care solutions company, today announced it has entered into a research collaboration agreement with Celsee Diagnostics, Inc., an innovator of human health products in the emerging field of liquid biopsy. The research project defined in the agreement aims to test the feasibility of Celsee’s liquid biopsy […]

Read more